

Serological extracellular matrix fragments may serve as early kidney damage biomarkers in children with defects in Alport genes

in collaboration with

\square		Ċ
	\mathbb{P}	C
6	GN	Ν

Österreichische Gesellschaft für Nephrologie

Solveig Groen¹, Federica Genovese¹, Christoforos Anagnostopoulos¹, Rebecca Preston², Rachel Lennon^{2,3}


¹ Nordic Bioscience. Cardiovascular and Renal Research, Herley, Denmark

² University of Manchester, Wellcome Centre for Cell-Matrix Research, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester, United Kingdom ³ Manchester Academic Health Science Centre, Department of Paediatric Nephrology, Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom

INTRODUCTION & AIM

Alport syndrome is a genetic disorder caused by variants in COL4A3, COL4A4, or **COL4A5**, which encode type IV collagen. The $\alpha 3.\alpha 4.\alpha 5$ (IV) collagen network is a critical structural component of the glomerular and tubular basement membranes within the kidney's extracellular matrix (ECM).

Type IV collagen triple helices



Variants in this network compromise basement membrane integrity, leading to cell injury, inflammation, and fibrotic remodeling of the surrounding interstitial **matrix**, which contributes to progressive kidney dysfunction

We aim to identify serological protease-generated fragments of the ECM as potential early biomarkers of kidney damage.

METHODS

Serological biomarkers quantified using ELISAs*

ECM degradation


C1SIG	Type I collagen
C3M	Type III collagen
C4M	Type IV collagen
C6M	Type VI collagen
NIC	Nidogen
LG1M	Laminin

ECM formation

PRO-C3 Type III collagen **PRO-C6** Type VI collagen

ECM turnover

PRO-C4 Type IV collagen



*ELISAs are developed by Nordic Bioscience

